The Investor
06 Apr 2026, 10:25
Kitsa has entered into a strategic partnership with Tech Mahindra to deploy agentic AI-driven medical writing solutions for pharmaceutical and biotechnology companies worldwide.
The collaboration integrates Kitsa’s KScribe AI platform into Tech Mahindra’s Life Sciences GenAI ecosystem, enabling faster and more efficient clinical trial protocol development and regulatory documentation. The joint solution aims to significantly reduce timelines for protocol creation—from 8–12 weeks to just a few days—while improving consistency and regulatory compliance.
Through this partnership, Tech Mahindra will expand its AI-powered medical writing capabilities to its global client base, helping pharmaceutical firms modernize clinical development workflows and accelerate study start-ups.
The solution will be available via AWS Marketplace, allowing enterprises to deploy AI-driven clinical documentation tools more quickly and securely using existing cloud infrastructure.
The collaboration integrates Kitsa’s KScribe AI platform into Tech Mahindra’s Life Sciences GenAI ecosystem, enabling faster and more efficient clinical trial protocol development and regulatory documentation. The joint solution aims to significantly reduce timelines for protocol creation—from 8–12 weeks to just a few days—while improving consistency and regulatory compliance.
Through this partnership, Tech Mahindra will expand its AI-powered medical writing capabilities to its global client base, helping pharmaceutical firms modernize clinical development workflows and accelerate study start-ups.
The solution will be available via AWS Marketplace, allowing enterprises to deploy AI-driven clinical documentation tools more quickly and securely using existing cloud infrastructure.